Skip to content
WeighLab
Menu
Ranked #253 · Grade C

Medro review

Medro is a telehealth brand (trademark pending, launched 2026) offering compounded semaglutide and tirzepatide across four commitment tiers — month-to-month down to 12-month — with no membership fee.

Visit Medro Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. See our disclosure.
Semaglutide
$199/mo (compounded)
Tirzepatide
$299/mo (compounded)
Coverage
All 50 states
Brand-name
Yes

Semaglutide · modeled / year

$2,388

Tirzepatide · modeled / year

$3,588

Pricing verified August 2026

The Index scorecard

Medro scored on our six Cost-Efficiency Index factors. See the methodology.

Normalized Cost/Month47/100
Price Transparency54/100
Nationwide Access86/100
Formulation Options79/100
Clinical Oversight63/100
Contract Flexibility33/100

Where the value is

  • Live pricing tiers for both semaglutide and tirzepatide are transparent and fully disclosed (month-to-month through 12-month) without needing to enter the intake flow
  • LegitScript-certified (seal #50716646, verified against legitscript.com) and available in all 50 states
  • Named clinical partner (Arora Health & Aesthetics, LLC — Dr. Sean Arora, NPI 1841729449, Seattle, WA) and named compounding pharmacy (The Pharmacy Hub, Miami, FL) — both real, both verifiable, though neither is surfaced in the site's marketing copy
  • No membership fee and 'same price, every dose' regardless of titration level

The tradeoffs

  • The lowest advertised rate ($149 semaglutide / $224 tirzepatide) requires a full 12-month prepaid commitment; the no-commitment month-to-month rate is 33% higher ($199/$299)
  • No mg dose is disclosed for any pricing tier — the plans are priced by commitment length only, so it's unclear what dose a given monthly price actually delivers
  • The named clinical partner and pharmacy only appear on legal/FAQ pages, not on the pricing or marketing pages a typical shopper would read
  • Very new brand (2026, trademark pending) with no independent track record

The bottom line

Best for: Shoppers who will commit to a longer plan to unlock Medro's lowest published tier. Medro is a telehealth brand (trademark pending, launched 2026) offering compounded semaglutide and tirzepatide across four commitment tiers — month-to-month down to 12-month — with no membership fee.

Ranked #253 of 539 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.

Compare with other providers

All 538 other providers we've modeled, in Cost-Efficiency Index order. See the ranked alternatives to Medro.

The 24 programs nearest this one

Pricing, states and verification reflect Medro's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on Medro's site. Not medical advice; see our disclosure.

← Back to the value leaderboard